HAMLET successful human trials featured in South China Morning Post
Following the successful human trial of the HAMLET drug candidate Alpha1H and publication of the results in Nature Communications, Hamlet Pharma and its founder Catharina Svanborg are the topic of an in-depth feature in South China Morning Post's Health & Wellness section, published on July 5th. South China Morning Post is Hong Kong-based and has a circulation of 105 000 with 197 million page views per month.
“We are pleased and very excited. It takes a dedicated team and very hard work to a discovery all the way to the clinic. It is wonderful to see beneficial effects for the cancer patients and no evidence of side effects so far. Publishing in a leading international journal such as Nature Communications also provides a quality stamp” says Catharina Svanborg, Chariman and CMO.
Read the full feature story here:
For more information, please contact
Catharina Svanborg, Chairperson of the board, Hamlet Pharma, +46 709 42 65 49
Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α-lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer.
This project is funded from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 954360.
Sprint Bioscience licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals
Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals. The license agreement covers exclusive global rights to the program. The agreement has a total potential value of up to USD 277 million,...
Sprint Bioscience utlicensierar cancerläkemedelsprogrammet Vps34 till Deciphera Pharmaceuticals
Sprint Bioscience AB (publ) meddelar idag att bolaget licensierat sitt cancerläkemedelsprogram Vps34 till det amerikanska läkemedelsbolaget Deciphera Pharmaceuticals. Licensavtalet avser de exklusiva globala rättigheterna till programmet. Avtalet har ett sammanlagt potentiellt värde på upp till 277...
Ectin Research AB publicerar utfall i bolagets emission inför notering
Den 29 juli 2021 avslutades teckningstiden i Ectin Research AB:s (”Ectin” eller ”Bolaget”) emission av units (aktier och teckningsoptioner) om totalt initialt cirka 55 MSEK inför notering på Spotlight Stock Market (”Spotlight”). Emissionen tecknades till totalt ci...
Bluelinea a levé près de 2 MEUR par l'exercice de BSA J afin d'accompagner son développement.
Bluelinea, opérateur majeur de la filière «Silver Économie» en France, est heureux d'annoncer le succès de son augmentation de capital par l'exercice des bons de souscription d'actions attribués gratuitement à tous les act...